NR4A1 and breast cancer: BC resistance to conventional therapies remains a significant obstacle to achieving durable remissions and cures across all metastatic subtypes, such as hormone-receptor-positive (HR+), HER2-positive, and triple-negative (TNBC) [8,10,34,66].